Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers

Emerging therapies in myeloproliferative disorders such as polycythemia vera and myelofibrosis could have the potential to shake up the landscape. But, according to Michael J. Mauro, MD there is a great deal of work ahead for researchers.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.